TG adds a multiple sclerosis string to its bow

One company set to have a very happy Christmas is TG Therapeutics. After enjoying a 13% rise on the back of haematology data at last weekend’s Ash meeting, its stock put on another 41% yesterday when two pivotal studies backed the use of its CD20 antibody ublituximab in multiple sclerosis.

True, the data put ublituximab on a collision course with Roche’s juggernaut Ocrevus, which derives much of its fame from activity in primary progressive MS, in which ublituximab has yet to be tested. But TG’s data should not be underestimated for the achievement they mark in the more competitive relapsing form of the disease.